2. Cytoskeleton Cell Cycle/DNA Damage MAPK/ERK Pathway Apoptosis Protein Tyrosine Kinase/RTK
  3. Pyk2 PAK Mixed Lineage Kinase FAK Src Apoptosis Syk
  4. 1370261-98-5

1370261-98-5

PRT062607 acetate Chemical Structure

1370261-98-5

Chemical Structure

  • PRT062607 acetate
  • Synonym(s): P505-15 acetate;PRT-2607 acetate;BIIB-057 acetate
  • CAS No: 1370261-98-5
    Formula: C21H27N9O3
    Molecular Weight: 453.50
  • IUPAC Name: 4-((3-(2H-1,2,3-triazol-2-yl)phenyl)amino)-2-(((1R,2S)-2-aminocyclohexyl)amino)pyrimidine-5-carboxamide acetate
  • InChIKey: ISHXQLKRUSVKDD-IDVLALEDSA-N
  • SMILES: NC(C1=CN=C(N[C@H]2[C@@H](N)CCCC2)N=C1NC3=CC=CC(N4N=CC=N4)=C3)=O.OC(C)=O

Biological Activity: PRT062607 (P505-15) acetate is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 acetate exerts potent antitumor activity in tumor xenograft mouse models[1].[2].

Cat. No. Product Name Purity Description
HY-15324 PRT062607 acetate 99.83% PRT062607 (P505-15) acetate is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 acetate exerts potent antitumor activity in tumor xenograft mouse models..

References

[1]. Spurgeon SE, et al. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. J Pharmacol Exp Ther. 2013 Feb;344(2):378-87. [Content Brief]
[2]. Coffey G, et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther. 2012 Feb;340(2):350-9. [Content Brief]

Keywords:

PRT062607 acetate